Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You might see it today.
How tough is it to belly up to the bar and pay 20 cents when it is selling around 50 cents?
Well let him make CYRX another success story. I am feeling real good about this stock for the first time in a long, long time!
It is getting interesting. Someone just bought 18,000 shares at .53
About 15% below what I had hoped for in gross sales. Next quarter target is $500,000.
If I understand you correctly you do not currently own any shares of CYRX ?
50,000 shares traded at .56 in after hours trading
At least we were mentioned in the release.
ZTS is the symbol and is up over 20% so far
If you GOOGLE Westcliff's holdings you will see they sold all of their holdings in CYRX last quarter. If I remember it was around 1.5 million shares.
All we can do is wait. We should have an earnings report in about 3 weeks, then I hope the company has an update type of conference call followed by another Zacks report.
Good press, very little dollars.
Per previous comments from the CEO, their policy will be to not release financial information regarding future contracts. Future income will be reflected in our earnings reports. He has also stated in the past that FED-X has not given permission to PR their relationship and it may be the same situation with Pfizer. I dislike it as much as anyone,but we will just have to live with it. We are just a minnow in a pond with the big sharks.The earnings reports later in the year will be very telling.
The pricing is being kept confidential so we will have to wait to see further financial reporting. I found it interesting, yet typical, that either party may cancel this agreement if the other party goes bankrupt. Hopefully they have been satisfied with Cryport's plan to survive.
I may have missed something but I don't believe there is a conference call for tomorrow. I think it's just another sophisticated dog and pony show that is being broadcast on the internet. Am I correct?
Let's not forget CYRX has to perform and make money on this deal. If they screw this up with Pfizer it's over.
Hope you're right but it will be tough with a down market, it's Friday plus the holiday season.
No, the IPO is 4 billion which translates into a company valuation of 20 billion
If it was a bigger name in the idustry they probably would but with such a small fish like Pfizer I don't think they will bother.
I couldn't agree more on the BFD but we are up a nickle with over 600,000 shares traded. Hopefully something is up.
Something is cookin and it don't smell too good!
CYRX: YoY and Sequential Revenue Growth Continues
By Zacks Equity Research | Zacks – 21 hours agoEmailShare1PrintRELATED QUOTESSymbol Price Change
CYRX 0.23 0.03
CYRX: YoY and Sequential Revenue Growth Continues
By Brian Marckx, CFA
10-Q Filed: Revenue, expenses, EPS all in-line with our numbers. YOY and sequential revenue growth continues…
On November 9th CryoPort (CYRX) filed their 10-Q for the fiscal 2013 second quarter ending September 30, 2012. Revenue, expenses and EPS were very much in-line with our numbers. And importantly, CYRX extended the streak on revenue growth, on both a yoy as well as sequential basis, to four straight quarters (from fiscal Q3 2012 through Q2 2013) indicating that shipping volume is gaining positive traction, albeit at a modestly increasing rate.
Q2 revenue of $234k was largely in-line with our $273k estimate and was up from $111k at Q2 2012 (+111% yoy) and $191k at Q1 2013 (+23% sequentially). Operating expenses of $1.4 million were slightly lower than our $1.5 million estimate and again benefited from CYRX's recently implemented cost-saving initiatives. Net income and EPS were ($1.55) million and ($0.04), compared to our ($1.59) million and ($0.04) estimates.
CYRX exited Q2 with $1.7 million in cash and equivalents, down from $3.0 million at the end of fiscal Q1 2012. Cash used in operations was $1.2 million. CYRX also repaid (per terms of the notes) $24k of principal on the related party notes ($708k o/s as of 9/30/12, 6% annual interest, principal repaid currently @ $8k/month with remainder due at 3/1/2015 maturity). In the 10-Q CYRX notes that they believe cash on hand and cash from operations should be sufficient to sustain operations through the end of fiscal 2013 (March 31, 2013).
We have made only minor adjustments to our model following Q2 results and continue to model sequential revenue growth throughout the remainder of fiscal 2013. We are maintaining our Outperform rating and $3.00/share price target.
Jerrell Shelton named CEO / President
CYRX's search for a CEO ended with the early November announcement that Jerrell (Jerry) Shelton, who weeks earlier was elected to the company's Board, was named as CryoPort's President and Chief Executive Officer. Mr. Shelton comes with an impressive background including a Harvard MBA and high-level executive positions and board posts at a number of technology and service organizations including IBM, The Thomson Corporation (Thomson Reuters), and Solera Holdings. Mr. Shelton has had consistent operational and financial success for predecessor organizations, much of which we think can potentially translate over to CryoPort including significantly growing revenues, increasing customer contracts, penetration of target markets, implementation of strategic vision, and, ultimately, increasing shareholder value. We had an introductory call with Mr. Shelton last week and came away confident that he shares the belief that CryoPort's shipper and logistics services can be a game-changer in cryogenic shipping and is energized and focused to make that a reality.
New and updated customer offerings
As CryoPort first announced on their 9/20/12 Business Update call (which we fully summarized in our 9/21/12 Investor Note), CryoPort is expanding their service offerings in order to appeal to a broader, more diverse customer base. This is in contrast to only offering customers their full-service CryoPort Express Shipper plus CryoPortal logistics service which had been the case in the past and may have left potential customers on the sideline as that one-size fits all approach didn't always fit with customer needs. The Q2 2013 10-Q describes in more detail CYRX's current customer offerings which we have included below.
Expanded Service Offerings which now include:
> Cryoport Express Solution: Cryoport's liquid nitrogen dry vapor shippers (Cryoport Express Shippers) including the Standard shipper (holds 75 2.0 ml vials) and the High Volume shipper (holds 500 2.0 ml vials). The service part of this offering is Cryoport's fully outsourced turn-key logistics solution which provides direct access to the cloud-based Cryoportal for order entry (which can also be done by contacting Cryoport client Care), 24/7/365 logistics services through its Client Care Team, and complete training and process management for each customer.
> Customer-Staged Solution: Cryoport ships multiple Cryoport Express Shippers to the customer (uncharged and in bulk) enabling the customer to charge the shippers at their facility, process its orders through the Cryoportal and then return the shippers to Cryoport after each shipment for cleaning, testing and refurbishing. Cryoport provides the 24/7/365 logistics services utilizing its Cryoportal logistics platform.
> Customer-Managed Solution: Cryoport ships a fully-charged Cryoport Express Shiiper(s) to the customer enabling them to utilize their internal expertise and manage all or a portion of the logistics services. as with the above solutions, the shippers are returned to Cryoport for cleaning, testing and refurbishing within a pre-determined time period.
> Customer Integrated Logistics: The Cryoport Logistics Team provides the full capability of the Cryoportal to provide complete logistics services while enabling the customer to utilize their own packaging solutions.
> Distribution Partnerships: Partnership arrangements with freight forwarder, integrators, and other logistics providers to be a part of their solution.
OUTLOOK
Management indicates that they continue to add customer accounts and are getting increased interest from clinical research organizations and pharmaceutical companies - these are the customer classes that potentially represent very significant opportunity for CryoPort, particularly over the long-term. This has recently started to translate into greater revenue traction. Through the most recent reporting period CYRX extended the streak on revenue growth, on both a yoy as well as sequential basis, to four straight quarters (from fiscal Q3 2012 through Q2 2013) indicating that shipping volume is gaining positive traction, albeit at a modestly increasing rate. Recent highlights include the addition of ACM Global and ImClone Systems as new customers beginning in late 2011. In addition, other life sciences companies, including diagnostic testing organizations are also showing meaningful interest. We view the recent turnover in CYRX's leadership which included the appointment of individuals with backgrounds of success in turnaround situations, growing customer count and revenues, implementation of strategy, and increasing shareholder value as highly positive. In addition to the new leadership we see several catalysts to near-term revenue growth including resolution of the issues related to FedEx and the CryoPortal interface, the recent addition of new shipper sizes, a new focus on qualifying customers and identifying the low-hanging fruit, and the newly introduced broader menu of shipper and service offerings to appeal to a more diverse customer base.
While the long, drawn-out tire-kicking process by potential customers which includes including running multiple test shipments will likely continue to be a necessary evil before some customers adopt the full CryoPort Express Solution, CYRX's new menu of offerings should now allow them to generate revenue from ancillary sources such as customers that only want the shippers or only logistics for (example) maybe a small volume cell line and may not require the long test-shipment process. Longer-term we still see the full shipper and service offering as the major driver of CYRX's revenue but, in the meantime, these ancillary offerings should provide a meaningful contribution to the top-line and help cash generation.
To access a free copy of the full CYRX research report, CLICK HERE.
Read the Full Research Report on CYRX
Zacks Investment Research
Nice close today.
Thank you
Do you have a link?
O well, I guess the rally is over.
I don't understand the 43 and 59 cent projections. We were above 50 cents in late June and things look much better now if we can trust the CEO's latest statements and have faith in FED-X. What am I missing, dilution?
FYI
Blog
Follow Zacks.com
See all from Zacks.com
Article Tools:
Stumble It Tweet It Facebook LinkedIn More Sharing ServicesShare It Referenced Stocks
FDX 100% Rate It
Posted 10/5/2012 1:14 PM by Zacks Equity Research from Zacks.com in Investing, Business, Stocks
0 comments | Like it Don't like it Referenced Stocks: CYRX, FDX
CYRX'sShippers Highlighted At FedEx Summit
By Brian Marckx, CFA
FedEx ( FDX ) held a healthcare industry summit in NYC this week which highlighted the ever-increasing globalization of healthcare and how the company is addressing the rapidly expanding demand of interconnectivity among participants all over the world. As FedEx press release indicates (see below), CryoPort's Express Dry Shipper and CryoPortal are clearly a critical part of FedEx's strategy to meet this "exponential" growth in the global healthcare industry.
Both Fred Smith, founder and current Chairman and CEO of FedEx, and Richard Smith, director of Life Sciences and Specialty Services, spoke at the event. A key theme was that growth in the healthcare industry including research and manufacturing is expected to be especially strong in developing markets such as China and India which makes it critical for there to be efficient shipping connectivity and reach between the U.S. and the rest of the world. As we've noted in our ongoing coverage of CYRX, key benefits of CryoPort's offering including a 10+ day holding time, stable temperature, environmentally friendly / non-hazardous, and web-based tracking make it an ideal solution for shipping long distances and across international borders.
Temperature-controlled shipping, including deep-frozen shipping, was highlighted as one key aspect with FedEx specifically pointing towards their FedEx Deep Frozen Shipping (which is CryPort's ( CYRX ) Express Dry Shipper and CryoPortal) as a recent enhancement which will help meet this growing global healthcare shipping demand.
From FedEx's 10/4/2012 press release talking about CryoPort's Shipper and Portal:
FedEx Deep Frozen Shipping: FedEx makes the transportation of deep-frozen material simpler than ever before, eliminating the need for dry ice or expensive rented shipping equipment. This value-add FedEx service provides customers dealing with deep frozen material-such as body fluids, tissue samples or medicines-with a ready-to-ship, super-cooled Dewar that holds a temperature below minus-150 degrees Celsius for up to 10 days. Dry ice, in contrast, must be replenished every 72 hours to maintain its temperature. Eliminating the need for dry ice also reduces customs clearance delays and helps ensure sensitive deliveries arrive on time and in pristine clinical condition. [1]
The entire press release can be seen here; http://www.businesswire.com/news/home/20121004005174/en/FedEx-Summit-Spotlights-%E2%80%9CBorderless-Healthcare%E2%80%9D
We cover CYRX with an Outperform rating. See below for access to our most recent report on CYRX.
Please visit Brian Marckx's coverage page at scr.zacks.com to access a free copy of the full research report.
[1] FedEx Summit Spotlights "Borderless Healthcare", FedEx.com, BusinessWire Oct. 4, 2012
Read more: http://community.nasdaq.com/News/2012-10/cyrxsshippers-highlighted-at-fedex-summit-analyst-blog.aspx?storyid=179514#ixzz28utOOgi2
Given the volume and price drop lately, there must be some real sweet news coming out tomorrow. More dilution?
Too bad it does not mention Cryoport.
162,000 shares traded at 12:12 pm ?
Let's keep our fingers crossed!
Is this good or bad news?
Shouldn't we be getting a lack of earnings report soon?
"The board continues their search for the candidate to fill the CEO job, which we understand could be a several-month long process - the message being that the board is not taking the decision lightly and is focused on getting the right person for the position." I can appreciate the fact that the board wants to find the right person, however should it really take "several months"?
This is great news. I will be buying more next week to average down.
I couldn't agree with you more but the latest release is regarding Leatherman not Wasserman. I know, what the hells the difference!
I don't know if it is just wishful thinking on my part, but why would someone put up 5 million dollars if they were not assured of something positive happening in the very near future?
How did it go with Trey?